Contact us
Contact us
My details
Minimum length of 8 characters.
Uppercase letter
Lowercase letter
Number
Contains a special character e.g. !, @, $, *
Patient Management Software
Request additional PMS support by contacting us. Email: contact@reframeosteoporosis.com.au
Success
Please choose health medical record.
Patient Analysis Software
Success
Please choose health medical record.
Thank you.
Please check the following details.
Thank you.
We will be in touch soon.
Thank you
for participating in the program.
Privacy Collection Statement
JHL Digital on behalf of Amgen Australia Pty Ltd (“Amgen Australia”) collects your personal information to enable us to improve the services offered by this website and to manage this website, which includes verifying your registration information and ensuring only registered healthcare professionals use the website. We also collect information about your use of our website through cookies. We will only be able to link this information to you personally if you have provided us personally identifying information whilst using the site. We may use the data we obtain through the use of cookies to customise your website experience by anticipating the information and services that may be of interest to you, to improve the functioning of our website by monitoring traffic in popular areas and to modify the services and information we provide to meet customer demand; and for our business purposes, including operation of our website, as well as research and product analyses to help us better market our products.
For this purpose, we may disclose your personal information to Amgen Australia’s related entities, as well as to trusted third parties and suppliers who assist us in providing our products and services, and market research agencies. These related entities and third parties may be located in other countries including the United States of America and in Europe and Asia. Amgen Australia remains accountable for all personal information it discloses and takes appropriate measures to ensure that the confidentiality of your information is safeguarded. For more information on privacy at Amgen Australia, including how you may access or correct your personal information or make a privacy complaint, please see our Amgen Privacy Policy or contact our Privacy Officer at: Mail: Attn: Privacy Officer, Amgen Australia Pty Ltd, Level 7, 123 Epping Road, North Ryde NSW 2113 Email: privacyoffice@amgen.com Tel: +61 2 9870 1333
Consent Statement to receive Amgen Australia communication by email on products and services
JHL Digital and Hahn Healthcare Pty Ltd working on behalf of Amgen Australia would like to keep you updated on Amgen Australia activities, products, educational and marketing programs and invite you to events relevant to you by sending emails. For the above purposes we may disclose your personal information to Amgen Australia’s related entities, as well as to trusted third parties and suppliers who assist us in providing our products and services. These related entities and third parties may be located in other countries including the United States of America and in Europe and Asia. Amgen Australia remains accountable for all personal information it discloses and takes appropriate measures to ensure that the confidentiality of your information is safeguarded.
You may also withdraw your consent to receive such messages at any time by following the instructions provided in each electronic message sent to you.
For more information on privacy at Amgen Australia, please see our Amgen Privacy Policy or contact our Privacy Officer- Mail: Attn: Privacy Officer, Amgen Australia Pty Ltd Level 7, 123 Epping Road, North Ryde NSW 2113 Email: privacyoffice@amgen.com Tel: +61-2-9870-1333
THIS WEBSITE IS INTENDED FOR AUSTRALIAN HEALTHCARE PROFESSIONALS ONLY
Terms of Use
PLEASE READ THESE TERMS OF USE CAREFULLY
These Terms of Use describe the terms and conditions applicable to your use of the Amgen Australia Pty Ltd’s (“Amgen”) Reframe Osteoporosis website (“website”) produced by JHL Digital.
Amgen may at any time revise or modify these Terms of Use or impose new conditions for use of this website. Such changes, revisions or modifications shall be effective immediately upon notice to you, which may be given by any means including, without limitation, posting on the website or by e-mail. Any use of the website by you after such notice shall be deemed to constitute acceptance of such changes, revisions or modifications. Amgen may modify its services at any time.
THIS WEBSITE DOES NOT PROVIDE MEDICAL OR PROFESSIONAL SERVICES ADVICE.
The content on this website is intended to be a general information resource in regard to the subject matter covered, and is provided solely on an “AS IS” and “AS AVAILABLE” basis. You are encouraged to confirm the information contained herein with other sources. Amgen is not engaged in rendering medical or similar professional services or advice via this website, and the information provided is not intended to replace independent considerations. You should not construe Amgen’s publication of this content as an endorsement by Amgen of the views expressed herein, or any warranty or guarantee of any strategy, recommendation, treatment, action, or application of medication or preparation made by the author of the content.
Amgen invites you to view, use and download a single copy of the website for your use. You are also permitted to download certain professional support and patient information which may be made available by Amgen. Except as otherwise provided on this page, no part of any content or software on the website may be copied, downloaded or stored in a retrieval system for any other purpose, nor may it be redistributed for any purpose, without the express written permission of Amgen. You understand that Amgen may discontinue, change, or restrict your use of the website for any reason without notice.
ALL CONTENT ON THE WEBSITE IS PROVIDED TO YOU ON AN “AS IS” “AS AVAILABLE” BASIS WITHOUT WARRANTY OF ANY KIND EITHER EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, AND NON-INFRINGEMENT. AMGEN MAKES NO WARRANTY AS TO THE ACCURACY, COMPLETENESS, CURRENCY, OR RELIABILITY OF ANY CONTENT AVAILABLE THROUGH THE WEBSITE. YOU ARE RESPONSIBLE FOR VERIFYING ANY INFORMATION BEFORE RELYING ON IT. USE OF THE WEBSITE AND THE CONTENT AVAILABLE ON THE WEBSITE IS AT YOUR SOLE RISK. AMGEN MAKES NO REPRESENTATIONS OR WARRANTIES THAT USE OF THE WEBSITE WILL BE UNINTERRUPTED OR ERROR-FREE. YOU ARE RESPONSIBLE FOR TAKING ALL NECESSARY PRECAUTIONS TO ENSURE THAT ANY CONTENT YOU OBTAIN FROM THE WEBSITE IS FREE OF VIRUSES.
The above exclusions may not apply in jurisdictions that do not allow the exclusion of certain implied warranties.
YOUR USE OF THE WEBSITE OR ANY CONTENT ON THE WEBSITE IS AT YOUR OWN RISK. AMGEN SPECIFICALLY DISCLAIMS ANY LIABILITY, WHETHER BASED IN CONTRACT, TORT, STRICT LIABILITY OR OTHERWISE, FOR ANY DIRECT, INDIRECT, INCIDENTAL, CONSEQUENTIAL, OR SPECIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH ACCESS TO OR USE OF THE WEB SITE, EVEN IF AMGEN HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, INCLUDING BUT NOT LIMITED TO RELIANCE BY ANY PARTY ON ANY CONTENT OBTAINED THROUGH THE USE OF THE WEBSITE, OR THAT ARISES IN CONNECTION WITH MISTAKES OR OMISSIONS IN, OR DELAYS IN TRANSMISSION OF, INFORMATION TO OR FROM THE USER, INTERRUPTIONS IN TELECOMMUNICATIONS CONNECTIONS TO THE WEBSITE OR VIRUSES, WHETHER CAUSED IN WHOLE OR IN PART BY NEGLIGENCE, ACTS OF GOD, WAR, TERRORISM, TELECOMMUNICATIONS FAILURE, THEFT OR DESTRUCTION OF, OR UNAUTHORIZED ACCESS TO THE WEBSITE, OR RELATED INFORMATION OR PROGRAMS.
If you violate any of these Terms of Use or if you misuse the website, you agree to defend, indemnify and hold harmless Amgen, its officers, directors, employees, agents and licensees from any and all liability including costs, expenses and attorneys’ fees that arise out of or are related to your violation or misuse.
Certain areas of this website enable you to submit e-mails, or otherwise provide feedback or information to Amgen.
You agree that by submitting content:
that you will not submit any information that would directly identify any individual or any information for which you do not have all necessary consents or authorisations to disclose;
you will only submit content that complies with applicable law, and will not submit content that is abusive, defamatory, obscene, infringing, threatening, repetitive, or otherwise inappropriate, or that contains any viruses or other software that may adversely affect the operation of another’s computer;
you understand and agree that such content that is submitted to a feedback page, will be deemed non-confidential; and
you grant to Amgen the irrevocable right to use, copy, modify, publish, perform, transmit and display such content via any media in accordance with these Terms of Use, and waive any moral rights you may have in such content. Subject to all applicable federal laws, Amgen shall be free to use such content, including any ideas, concepts, know-how, or techniques contained in such content, for any reason whatsoever.
All Amgen trademarks are the exclusive property of Amgen or companies within the Amgen group. Unauthorised use of any trademark, service mark or logo may be a violation of trademark laws.
This website is protected by Australian and foreign copyright laws. Except for your informational, personal, non-commercial use as authorised above, you may not modify, reproduce or distribute the design or layout of the website or individual sections of the design or layout of the website or Amgen logos without Amgen’s written permission.
The website contains information, news and/or press releases in relation to cardiovascular disease, familial hypercholesterolemia and other cardiology conditions, as well as certain Amgen products. While this information was believed to be accurate as of the date it was prepared, Amgen disclaims any duty or obligation to update this information, news or any press releases. Information about companies other than Amgen contained in the news, press releases or otherwise, should not be relied upon as being provided or endorsed by Amgen.
The website may contain links to websites operated by other parties. The linked sites are not under the control of Amgen, and Amgen is not responsible for the content available on any other Internet sites linked to the website. Such links do not imply Amgen’s endorsement of material on any other site and Amgen disclaims all liability with regard to your access to such linked websites. Amgen provides links to other Internet sites as a convenience to users, and access to any other Internet sites linked to this website is at your own risk.
This website requires you to register prior to permitting access to the website or certain services available on this site. You are responsible for maintaining the confidentiality of your registration information and password, and for all uses of your password, whether or not authorised by you.
This website is operated by Amgen from its offices in New South Wales, Australia. The law of the State of New South Wales and Australia shall govern these terms and conditions, without reference to its choice of law rules. Amgen makes no representation that the information in the website is appropriate or available for use in other locations, and access to this website from territories where the content of this website may be illegal is prohibited. Those who choose to access this website from other locations do so on their own initiative and are responsible for compliance with applicable local laws.
Any controversy or claim arising under or related to these Terms of Use or Amgen’s products and/or services shall be submitted to courts of competent jurisdiction in New South Wales and courts entitled to hear appeals therefrom.
Amgen reserves the right to seek all remedies available at law and in equity for violations of these Terms of Use, including the right to block access from a particular Internet address to the website.
All personal information will be collected, used and disclosed by JHL Digital for the purposes of administering Reframe Osteoporosis™ (in accordance with the privacy collection statement appearing on this website).
If you have any questions about these Terms of Use, please contact us.
THIS WEBSITE IS INTENDED FOR AUSTRALIAN HEALTHCARE PROFESSIONALS ONLY
Nominate a Signee for
Add Clinic User to sign MPAA
Does the user have a REFRAME account?
REFRAME Medical Practice Activity Agreement (MPAA)
What is this document?
REFRAME is an education and chronic disease management program supported by Amgen Australia PTY Limited (Amgen), a Biotechnology company that is a member of Medicines Australia (https://medicinesaustralia.com.au). This document, REFRAME Medical Practice Activity Agreement (MPAA) outlines that Amgen is providing the support of a REFRAME Nurse Educator (RNE) and/or REFRAME Educator (RE) to educate and train healthcare professionals in your practice on chronic diseases, including but not limited to osteoporosis and/ or cardiovascular disease. This education will include methods that may include but are not limited to, using practice computer systems and software, ‘mail-merge’ and SMS-call systems to assist in identifying and managing patients who suffer from a chronic illness (e.g. osteoporosis and cardiovascular events etc), as agreed by the practice and RNE and/or RE with the aim of assisting practices to be self-sufficient long term. The RNE and/or RE may further support the practice with printed and online resources for healthcare professionals and their patients to improve the diagnoses and management of chronic diseases (e.g., osteoporosis, cardiovascular disease etc). Furthermore, practice staff will be able to access the REFRAME Website, a site restricted to healthcare professionals, upon individual registration for the REFRAME Website. The Website provides access to educational materials and chronic disease management tools and supports the REFRAME Medical Practice Activity. Amgen’s support will be acknowledged in all REFRAME materials, educational and patient materials, and website.
The team of REFRAME Nurse Educators (RNE) and/or REFRAME Educators (RE) are contracted by DKSH Healthcare Australia Pty LTD on behalf of Amgen and trained to work directly with participating general practice staff. Interactions with the RNE/RE will occur at a frequency and duration agreed on by the RNE/RE and the participating general practice. Patient privacy: To train your practice staff, the RNE/RE may encounter individual patient information. This information will not be used, collected, or analysed by the RNE/RE, nor will copies of this information be taken from your practice. For further information about Amgen’s privacy statement, please visit: http://www.amgen.com.au/privacy-statement/ for more information. Why am I being asked to sign? Signing this agreement means that you permit:
If you choose to sign, you may terminate the agreement at any time. This Medical Practice Activity Agreement (“Agreement”) is dated and effective the first date of execution below (“Effective Date”) and is entered into by and between: Amgen Australia Pty Ltd (ABN 31 051 057 428) of Level 11, 10 Carrington Street NSW 2000 (“Amgen”);
And
Amgen and Recipient are collectively referred to as “the parties”.
This agreement sets forth the terms and conditions under which Recipient, the recipient of the below defined and detailed Medical Practice Activity, will be supported by Amgen. This Agreement is effective as of the date the last party signs this Agreement (“Effective Date”).
1. Period of Support
The Amgen supported Medical Practice Activity Agreement will be provided to Recipient at dates and times to be mutually agreed between the parties for a period of 24months commencing from the Effective Date, unless terminated earlier in accordance with Clause 11 of this Agreement. Amgen reserves the right to cancel the program at any point in time and will inform the Recipient if it decides to do so.
2. Dates/Location(s) of Support
Amgen will provide the REFRAME Medical Practice Activity at Recipient’s primary place of business at the address detailed above and on dates and times mutually agreed between the parties. However, Amgen or its representatives reserve the right to change these dates with reasonable notice. Educational support delivered by either the RN and/or RE will be limited up to 35-hours for the delivery of the REFRAME program(s) and its materials.
3. Publications
Amgen is supportive of any publication or presentation which results from this activity, particularly in furthering the screening and management of chronic illness. In line with Amgen’s internal publication requirements, Amgen would require the following be observed: A separate agreement outlining details and intent of publication or presentation derived from the work, pertaining to the REFRAME/medical activity and must contain a statement acknowledging Amgen’s support.
4. No Payments
For the avoidance of doubt, no payments are being made by Amgen or any Amgen representative to Recipient in connection with the Medical Practice Activity detailed herein.
5. Safety
Reporting suspected adverse reactions (side effects) once a product is marketed is important as it allows continued monitoring of the benefits and risks of medicines and identification of any new side effects. Managing adverse reactions depends on healthcare professionals and consumers reporting them - please consider this when such information is brought to your attention. You are reminded that any suspected adverse reactions, other safety findings, or product related quality complaints involving an Amgen product are to be reported to Amgen Safety at medinfo.JAPAC@amgen.com
6. Confidentiality and Intellectual Property
Recipient, its practice and its representatives shall, for a period of five (5) years from the Effective Date, keep confidential the REFRAME materials received by or disclosed to Recipient by Amgen or its representatives in any form, including, without limitation, materials and information accessed via the REFRAME website (“Confidential Information”) and will not disclose to any third party or use it for any purpose except as provided in this Agreement or as otherwise indicated in writing by Amgen. Recipient acknowledges it has no proprietary rights whatsoever in the Confidential Information. The obligations set forth in the above paragraph shall not apply to any portion of Confidential Information which (i) is or later becomes generally available to the public by use, publication or the like, through no act or omission of Recipient; (ii) Recipient possessed prior to the Effective Date of this Agreement without being subject to an obligation to keep such Confidential Information confidential; (iii) is lawfully obtained without restriction from a third party who had the legal right to disclose the same to Recipient; or (iv) is independently developed by Recipient without the use or benefit of Confidential Information as evidenced by the Recipient’s written records. If Recipient is required to disclose any of the above-mentioned information in response to a valid order of a court or other governmental body, it may do so subject to providing Amgen with timely prior written notice (at the latest within five (5) business days) and coordinating with Amgen in order to limit the scope of such required disclosure. All Intellectual Property Rights (including present and future rights, title and interest, including discovery rights, invention rights, copyright, design rights, and patent rights) existing prior to the date of this Agreement shall remain the property of the party introducing the same. Recipient acknowledges that the disclosure of information to Recipient by or on behalf of Amgen shall not result in any obligation upon Amgen to grant Recipient any rights in and to that information.
7. Disclosure
Recipient acknowledges and agrees that, to the extent required or necessary to comply with applicable laws and codes of practice on disclosure obligations, Amgen shall have the right to publicly disclose information regarding Recipient (and if required, its staff) and this Agreement and that information may include without limitation the following: (i) dates and description of the Medical Practice Activity; and (ii) Recipient’s name and address. All costs associated with educational material, website and time spent by the RNE/RE at the recipient address is paid by Amgen with no cost to the Recipient.
8. Privacy
Recipient shall not provide or otherwise disclose to Amgen any information that could be used to identify individual patients. Any patient-level data that may be accessible to Amgen must be de-identified. For more information on privacy at Amgen, including how you can make a privacy complaint, please see our privacy statement available at https://www.amgen.com.au/privacy-statement/ or contact our Privacy Officer at Mail: Attn. Privacy Officer, Amgen Australia Pty Ltd. Level 11, 10 Carrington Road, NSW 2000. Email: Privacy@amgen.com, For Recipient’s healthcare professional staff to access the Website they will each be required to register for the Website. Personal information is collected at the time of registration pursuant to the privacy collection notice and terms of use appearing on the Website. The RNE/RE working with your practice may encounter patient information, and this information will be accessed only in accordance with the delivery of education to practice staff in accordance with the Medical Practice Activity. For the purposes of tracking the progress of the practice in completing the program and the effectiveness of REFRAME programs in meeting their objective of improving patient screening and management, the RNE/RE will collect aggregated data from the recipient.
9. Disclaimer
Recipient’s participation in the Medical Practice Activity is not conditional upon any obligation by the healthcare professional/s involved to recommend, prescribe, dispense or administer Amgen’s products or services. This Agreement must not interfere with the independence of a healthcare professional’s practice. Amgen is providing the Medical Practice Activity in accordance with the Medicines Australia Code of Conduct. Recipient and Amgen acknowledge and agree that the provision of the Medical Practice Activity is not intended, directly or indirectly, to compensate Recipient or Recipient healthcare professional staff for recommending, prescribing, dispensing or administering Amgen’s products or services.
10. Anti-bribery and corruption
Recipient represents, warrants and covenants, as of the Effective Date of this Agreement to and through the expiration or termination of this Agreement, (1) that Recipient, and, to the best of Recipient’s knowledge, Recipient’s owners, directors, officers, employees, or any agent, representative, subcontractor or other third party acting for or on Recipient’s behalf (collectively, “Representatives”), shall not, directly or indirectly, offer, pay, promise to pay, or authorise such offer, promise or payment, of anything of value, to any individual or entity for the purposes of obtaining or retaining business or any improper advantage in connection with this Agreement, or that would otherwise violate any applicable laws, rules and regulations concerning or relating to public or commercial bribery or corruption (“Anti-Corruption Laws”) and (3) that Amgen may terminate this Agreement (a) if Recipient’s Representatives fail to comply with the Anti- Corruption Laws or with this paragraph, or (b) if Amgen has a good faith belief that Recipient or Recipient’s Representatives has violated, intends to violate, or has caused a violation of the Anti-Corruption Laws.
11. Miscellaneous
This Agreement constitutes the entire agreement between Amgen and Recipient with respect to the subject matter contained herein and supersedes all prior oral or written agreements and understandings between the parties. No modification of this Agreement will be effective unless made in writing and signed by Amgen and Recipient. This Agreement is governed by laws applicable in the state of New South Wales, Australia and the parties submit to the exclusive jurisdiction of that state. The parties have executed this Agreement to be effective on the Effective Date. This Agreement may be executed in any number of counterparts, using e-signature tools such as DocuSign or similar electronic signature software. All counterparts together will be taken to constitute one instrument.
Or type your name below twice to sign
Welcome
Please set your password first.
Minimum length of 8 characters.
Uppercase letter
Lowercase letter
Number
Contains a special character e.g. !, @, $, *
Do you want to add this user to your dashboard?